The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease

European Journal of Clinical Investigation, Supplement

Volumn 35, Issue 3, 2005, Pages 58-65

  McClellan, William M ^a,b,c   Jurkovitz, C ^b   Abramson, J ^b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Medicine ^*  (United States)

Author keywords

Anaemia; Chronic kidney disease; NHANES

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; CHRONIC KIDNEY DISEASE; CHRONIC PATIENT; CREATININE CLEARANCE; DIALYSIS; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PLASMA VOLUME; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 28944451243     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01532.x     Document Type: Review

References (56)

1. Sawyer ST, Penta K. Erythropoietin cell biology. Hematol Oncol Clin North Am 1994;8:895-911.
2. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:806-10.
3. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-4.
4. Jelkmann W. Erythropoietin, structure, control of production, and function. Physiol Rev 1992;72:449-89.
5. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622-30.
6. Eckardt KU. Anaemia in end-stage renal disease: pathophysiological considerations. Nephrol Dial Transplant 2001;16 (Suppl. 7):2-8.
7. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993;44:1149-62.
8. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 2001;38:415-25.
9. Naets JP, Garcia JF, Tousaaint C, Buset M, Waks D. Radioimmunoassay of erythropoietin in chronic uraemia or anephric patients. Scand J Haematol 1986;37:390-4.
10. Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 1979;54:877-84.
11. Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979;93:449-58.
12. Jensen JD, Madsen JK, Jensen LW, Pedersen EB. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 1994;5:177-85.
13. Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002;13:1288-95.
14. Stone WJ, Graber SE, Krantz SB, Dessypris EN, O'Neil VL, Olsen NJ et al. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. Am J Med Sci 1988;296:171-9.
15. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321:158-63.
16. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 1989;14:486-95.
17. Frenken LA, Verberckmoes R, Michielsen P, Koene RA. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant 1989;4:782-6.
18. Austrian Multicenter Study Group. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Austrian Multicenter study Group of r-HuEPO in Predialysis Patients. Nephron 1992;61:399-403.
19. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994;24:777-84.
20. Kulzer P, Schaefer RM, Krahn R, Schaefer L, Heidland A. Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. European Multicentre Study Group. Im J Artif Organs 1994;17:195-202.
21. Int J Artif Organs 5:177-85.
22. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999;33:1122-30.
23. Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P et al. Recombinant human erythropoietin treatment in pre-dialysis patients. Ann Intern Med 1989;110:108-14.
24. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR et al Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-54.
25. Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R et al. Management of patients with chronic renal insufficiency in the northeastern United States. J Am Soc Nephrol 2001;12:1501-7.
26. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19 (Suppl. 2):iil-ii47.
27. Anon. National Kidney Foundation Dialysis outcomes quality initiative. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30 (Suppl. 3):S192-240.
28. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, Collins AJ. Trends in anemia at initiation of dialysis in the United States. Kidney Int 2001;60:1875-84.
29. Strauss MJ, Port FK, Somen C, Wolfe RA. An estimate of the size of the US predialysis population with renal insufficiency and anemia. Am J Kidney Dis 1993;21:264-9.
30. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia. The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-8.
31. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int 2001;59:725-3.
32. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States. Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-10.
33. Ifudu O, Dawood M, Friedman EA. Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure. Nephron 1997;77:315-8.
34. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803-12.
35. Mafra D, Cuppari L, Cozzolino SM. Iron and zinc status of patients with chronic renal failure who are not on dialysis. J Ren Nutr 2002;12:38-41.
36. Jungers PY, Robino C, Choukroun G, Nguyen-Khoa T, Massy ZA, Jungers P. Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant 2002;17:1621-7.
37. Comment in: Nephrol Dial Transplant 2003 Mar;18(3):623.
38. McClellan W, Tran L. The prevalence of anemia in patients with chronic kidney disease: final results from the PAERI study (Abstract). J Am Soc Nephrol 2002;13:461A.
39. Valderrabano F, Hörl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. Pre-dialysis survey on anaemia management. Nephrol Dial Transplant 2003;18:89-100.
40. Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl 2002;80:44-8.
41. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:1908-14.
42. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998;32 (Suppl. 4):S133-41.
43. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348-55.
44. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002;40:1153-61.
45. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-36.
46. Langston RD, Presley R, Flanders WD, McClellan WM. Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction admitted to community hospitals: a population-based study. Kidney Int 2003;64:1398-405.
47. Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000;15:650-8.
48. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int 2002;61 (Suppl. 80):S35-8.
49. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003;64:610-5.
50. Jurkovitz CT, Abramson J, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003;14:2919-25.
51. Rossert JA, McClellan WM, Roger SD, Verbeelen DL, Hörl WH. Contribution of anaemia to progression of renal disease: a debate. Nephrol Dial Transplant 2002;17 (Suppl. 1):60-6.
52. Rossert J, McClellan WM, Roger SD, Verbeelen DL. Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression? Nephrol Dial Transplant 2002;17:359-62.
53. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronicrenal failure, especially in nondiabetic patients. Nephron 1997;77:176-85.
54. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-12.
55. Mohanram A, Zhang J, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-8.
56. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anemia. Nephrol Dial Transplant 2000;15:S14-8.